

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1805jxb

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 01 INPADOC: New family current-awareness alert (SDI) available  
NEWS 4 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 5 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX  
NEWS 6 SEP 27 STANDARDS will no longer be available on STN  
NEWS 7 SEP 27 SWETSCAN will no longer be available on STN  
NEWS 8 OCT 28 KOREAPAT now available on STN  
NEWS 9 NOV 18 Current-awareness alerts, saved answer sets, and current  
search transcripts to be affected by CERAB, COMPUAB, ELCOM,  
and SOLIDSTATE reloads  
NEWS 10 NOV 30 PHAR reloaded with additional data  
NEWS 11 DEC 01 LISA now available on STN  
  
NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:09:45 ON 03 DEC 2004

=> file .pub

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 11:10:10 ON 03 DEC 2004

FILE 'BIOSIS' ENTERED AT 11:10:10 ON 03 DEC 2004  
Copyright (c) 2004 The Thomson Corporation.

=> s ekins s/au

L1 29 EKINS S/AU

=> e ekins s/au

E1	3	EKINS ROGER P/AU
E2	1	EKINS ROGER PHILIP/AU
E3	29 -->	EKINS S/AU
E4	66	EKINS SEAN/AU
E5	2	EKINS W L/AU
E6	1	EKINTUMAS D/AU
E7	1	EKIRIWANG JAMES T/AU
E8	10	EKIS G/AU
E9	2	EKIS IMANTS/AU
E10	6	EKIS M/AU
E11	1	EKIS M L/AU
E12	4	EKISA E G/AU

=> s e3-4

L2 95 ("EKINS S"/AU OR "EKINS SEAN"/AU)

=> s l2 and 3d/4d-qsar and cyp2d6

'4D-QSAR' IS NOT A VALID FIELD CODE

'4D-QSAR' IS NOT A VALID FIELD CODE

L3 0 L2 AND 3D/4D-QSAR AND CYP2D6

=> s l2 and cyp2d6

L4 15 L2 AND CYP2D6

=> s l4 and (four dimensional)

L5 2 L4 AND (FOUR DIMENSIONAL)

=> d 1-2 bib ab

L5 ANSWER 1 OF 2 MEDLINE on STN

AN 2000242567 MEDLINE

DN PubMed ID: 10780267

TI Three and **four dimensional**-quantitative structure activity relationship (3D/4D-QSAR) analyses of **CYP2D6** inhibitors.

AU **Ekins S**; Bravi G; Binkley S; Gillespie J S; Ring B J; Wikel J H; Wrighton S A

CS Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA.

SO Pharmacogenetics, (1999 Aug) 9 (4) 477-89.

Journal code: 9211735. ISSN: 0960-314X.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200005

ED Entered STN: 20000525

Last Updated on STN: 20000525

Entered Medline: 20000512

AB Three- and **four-dimensional** quantitative structure activity relationship (3D/4D-QSAR) pharmacophore models of competitive inhibitors of **CYP2D6** were constructed using data from our laboratory or the literature. The 3D-QSAR pharmacophore models of the common structural features of **CYP2D6** inhibitors were built using the program Catalyst (Molecular Simulations, San Diego, CA, USA). These 3D-QSAR models were compared with 3D and 4D-QSAR partial least squares (PLS) models which were constructed using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors of size and shape of inhibitors. The first Catalyst model was generated from multiple conformers of competitive inhibitors (n = 20) of **CYP2D6** mediated bufurololol 1'-hydroxylation. This model demonstrated a correlation of observed and predicted Ki (apparent) values of r = 0.75. A second Catalyst model was constructed from literature derived Ki (apparent)

values (n = 31) for the inhibition of **CYP2D6**. This model provided a correlation of observed and predicted inhibition for **CYP2D6** of  $r = 0.91$ . Both Catalyst Ki pharmacophores were then validated by predicting the Ki (apparent) of a test set of known **CYP2D6** inhibitors (n = 15). Ten out of 15 of these Ki (apparent) values were predicted to be within one log residual of the observed value using our **CYP2D6** inhibitor model, while the literature model predicted nine out of 15 values. Similarly, 3D- and 4D-QSARs derived from PLS MS-WHIM for our dataset yielded predictable models as assessed using cross-validation. The corresponding cross-validated PLS MS-WHIM model for the literature dataset yielded a comparable 3D-QSAR and improved 4D-QSAR value. Such computational models will aid in future prediction of drug-drug interactions.

L5 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 1999:443060 BIOSIS  
DN PREV199900443060  
TI Three and **four dimensional**-quantitative structure  
activity relationship (3D/4D-QSAR) analyses of **CYP2D6**  
inhibitors.  
AU **Ekins, Sean**; Bravi, Gianpaolo; Binkley, Shelly; Gillespie,  
Jennifer S.; Ring, Barbara J.; Wikel, James H.; Wrighton, Steven A.  
[Reprint author]  
CS Department of Drug Disposition, Lilly Research Laboratories, Lilly  
Corporate Center, Eli Lilly and Co., Indianapolis, IN, 46285, USA  
SO Pharmacogenetics, (Aug., 1999) Vol. 9, No. 4, pp. 477-489. print.  
ISSN: 0960-314X.  
DT Article  
LA English  
ED Entered STN: 26 Oct 1999  
Last Updated on STN: 26 Oct 1999  
AB Three- and **four-dimensional** quantitative structure  
activity relationship (3D/4D-QSAR) pharmacophore models of competitive  
inhibitors of **CYP2D6** were constructed using data from our  
laboratory or the literature. The 3D-QSAR pharmacophore models of the  
common structural features of **CYP2D6** inhibitors were built using  
the program Catalyst(R) (Molecular Simulations, San Diego, CA, USA).  
These 3D-QSAR models were compared with 3D and 4D-QSAR partial least  
squares (PLS) models which were constructed using molecular  
surface-weighted holistic invariant molecular (MS-WHIM) descriptors of  
size and shape of inhibitors. The first Catalyst(R) model was generated  
from multiple conformers of competitive inhibitors (n = 20) of  
**CYP2D6** mediated bufurolol 1'-hydroxylation. This model  
demonstrated a correlation of observed and predicted Ki (apparent) values  
of  $r = 0.75$ . A second Catalyst(R) model was constructed from literature  
derived Ki (apparent) values (n = 31) for the inhibition of **CYP2D6**.  
This model provided a correlation of observed and predicted inhibition  
for **CYP2D6** of  $r = 0.91$ . Both Catalyst(R) Ki pharmacophores were  
then validated by predicting the Ki (apparent) of a test set of known  
**CYP2D6** inhibitors (n = 15). Ten out of 15 of these Ki (apparent)  
values were predicted to be within one log residual of the observed value  
using our **CYP2D6** inhibitor model, while the literature model  
predicted nine out of 15 values. Similarly, 3D- and 4D-QSARs derived from  
PLS MS-WHIM for our dataset yielded predictable models as assessed using  
cross-validation. The corresponding cross-validated PLS MS-WHIM model for  
the literature dataset yielded a comparable 3D-QSAR and improved 4D-QSAR  
value. Such computational models will aid in future prediction of  
drug-drug interactions.

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.01

6.22

STN INTERNATIONAL LOGOFF AT 11:13:24 ON 03 DEC 2004